Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $878.0M | $750.9M |
| Cost of revenue | $0 | $0 | $525.9M | $425.6M |
| Gross profit | $0 | $0 | $352.1M | $325.3M |
| Gross margin | — | — | 40.1% | 43.3% |
| R&D | $0 | $0 | $0 | $0 |
| Operating income | −$1.3K | −$1.0M | −$78.5M | $48.0M |
| EBITDA | −$1.3K | −$1.0M | −$23.3M | $20.8M |
| Net income | −$1.3K | −$1.0M | −$64.7M | $35.5M |
| Net margin | — | — | -7.4% | 4.7% |
| EPS (diluted) | 0.00 | -0.03 | -1.22 | 0.47 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds FTIV.
No tracked institution reports a position in FTIV as of their last filing.
No one on the platform has traded FTIV yet.
| +0.00% |
| $1.1B |
| — |
| HUMAHumacyte, Inc. | $0.80 | +12.74% | $134M | — |
| HYACHaymaker Acquisition Corp. III | $10.75 | +2.28% | $314M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.